| Study Number | Completed Clinical Trial Report Summaries |
1033GR/0001 ARNO | A prospective, multi-centre, randomised, open parallel group study to compare the effectiveness and compatibility of ARIMIDEX (ZD 1033) with NOLVADEX after a prior 2 years’ treatment with tamoxifen in adjuvant therapy of breast carcinoma in postmenopausal women |
1033IL/0029 ATAC | A Randomised, Double-blind Trial Comparing ARIMIDEX™ Alone with NOLVADEX™ Alone with ARIMIDEX and NOLVADEX in Combination, as Adjuvant Treatment in Postmenopausal Women with Breast Cancer |
1033IA/0029 | A Randomised, Double-blind Trial to Assess the Pharmacokinetics of ARIMIDEX™ Alone, NOLVADEX™ Alone, or ARIMIDEX and NOLVADEX in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
1033IC/0029 | A Randomised, Double-blind Trial to Assess the Incidence of Endometrial Changes with ARIMIDEX™ Alone, NOLVADEX™ Alone, or ARIMIDEX and NOLVADEX in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
D5392C01985 (1033ID/0029) | A Randomised, Double-blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of ARIMIDEX™ Alone, NOLVADEX™ Alone, or ARIMIDEX and NOLVADEX in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women. |
| 1033IE/0029 | A Randomised, Double-blind Trial to assess Quality of Life with ARIMIDEX™ Alone, NOLVADEX™ Alone, or ARIMIDEX and NOLVADEX in Combination, when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women |
1033IL/0027 | A Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy and Safety of ARIMIDEX™ (ZD1033 1 mg Daily) with Tamoxifen (20 mg Daily) as First-line Therapy for Advanced Breast Cancer in Postmenopausal Women |
1033IL/0030 TARGET | A Randomized, Double-blind Trial to Compare the Efficacy and Safety of Anastrozole (ARIMIDEX™ 1 mg Daily) With Tamoxifen Citrate (20 mg Daily) as First-line Therapy for Advanced Breast Cancer in Postmenopausal Women |
1033IL/0039 PROACT | A randomised, double-blind, study comparing ARIMIDEX™ with NOLVADEX™ as neo-adjuvant and adjuvant treatment in postmenopausal women with large operable (T2 [≥3 cm], T3, N0-2, M0) or potentially-operable, locally advanced (T4b, N0-2, M0), ER+ and/or
PR+ breast cancer |
1033IL/0030 and 1033IL/0027 | Randomised, Double-blind Trials to Compare the Efficacy and Safety of ARIMIDEX™ (Anastrozole 1 mg Daily) with Tamoxifen (20 mg Daily) as First line Therapy for Advanced Breast Cancer in Postmenopausal Women: Safety and Survival Update 2001 |
1033AU/0001
ABCSG 6A | A randomised, open, comparative multicentre trial (Protocol 6a) in postmenopausal patients with breast cancer who have been treated with Tamoxifen postoperatively for 5 years as adjuvant hormone-therapy comparing the aromatase inhibitor Anastrozole for 3 years with an untreated controlgroup. |
1033US/0006 | A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Anastrozole (ZD1033, ARIMIDEX™) versus Placebo for the Treatment of Gynecomastia in Pubertal Boys. |
D5392NL002 ARREST | Arimidex; Reason for and effect of change from tamoxifen |
D5392C00050 SABRE | A multicentre phase III/IV study, of the effects of risedronate sodium (ACTONEL™, 35 mg/week, oral) on bone, in postmenopausal women, with hormone-receptor-positive early breast cancer, treated with anastrozole
(ARIMIDEX™, 1 mg/day oral) with either high-risk of fragility fracture (open-label, non-comparative stratum), or moderate-risk of fragility fracture (randomised, double-blind stratum), and of the effects of anastrozole
(ARIMIDEX™, 1 mg/day oral) on bone, in postmenopausal women, with hormone-receptor-positive early breast cancer, and low-risk of fragility fracture (open-label, non-comparative stratum) |
D5394C00046 | An Open-label Study Evaluating the Safety and Efficacy of Anastrozole (ARIMIDEX™) in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome. |
D5394C00001 | An Open-label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (ARIMIDEX™) Used to Treat Pubertal Boys with Gynecomastia of Recent Onset |
NIS-ARO-HCH-2006-1 | ARIMIDEX Study ( Non-interventional study to evaluate Arimidex in adjuvant therapy in partial or complete response or stabilized disease after first line chemotherapy in postmenopausal women with advanced breast cancer). |